Patent Grant
11970798
The present invention relates to a prosthetic fabric equipped with barbs, said fabric being covered, at least partially, with a bioresorbable microporous layer. Such a fabric can particularly be used for producing wall-reinforcing prostheses intended to be introduced into a patient by coelioscopy.
Wall-reinforcing prostheses, for example prostheses for reinforcing the abdominal wall, are widely used in the surgical field. These prostheses are intended for treating hernias by temporarily or permanently filling a tissue defect. These prostheses are generally made from a biocompatible prosthetic fabric and may have several shapes, rectangular, round, oval, depending on the anatomical structure to which they must be fitted. Some of these prostheses are made from entirely bioresorbable yarns and are intended to disappear after having carried out their reinforcing role until cell colonization takes place and tissue rehabilitation takes over. Other prostheses comprise non-bioresorbable yarns and are intended to remain permanently in the body of the patient.
Some of these prostheses are made from a knit, weaving or else non-woven arrangement of yarns, comprising barbed naps that protrude outwards from one face of the prosthesis: these barbs constitute hooks capable of being fastened either to another prosthetic fabric, belonging to the same prosthesis or not, or directly to the biological tissues, such as for example the abdominal wall. Certain prostheses may also comprise barbs on each of their two faces.
Furthermore, for the sake of minimizing the traumatisms subsequent to any surgical operation, patients are increasingly often operated on via coelioscopic surgery when the type of operation carried out permits it. Coelioscopic surgery requires only very small incisions, through which a trocar is passed, within which the prosthesis is conveyed to the implantation site. Thus open surgery is avoided and the patient can leave hospital rapidly. Coelioscopic surgery is particularly popular in surgical operations carried out in the abdomen, such as for example the treatment of hernias.
However, the trocars used in coelioscopic surgery generally have a relatively small calibrated diameter, which may vary, for example, from 5 to 15 mm, in order to reduce the size of the incision made as much as possible. The prosthesis must therefore be conveyed within a channel of reduced diameter and it must then be deployed to the implantation site.
In order to carry out this step, the prosthesis is generally wound around on itself in order to make it slide in the channel of the trocar or directly introduced by force. However, when the prosthetic fabric forming the prosthesis comprises barbs on one face, it may happen that these barbs become entangled in the body of the fabric and upset the subsequent deployment of the prosthesis at the implantation site. Furthermore, due to the fact that they are not protected, the barbs may be damaged during the unrolling of the prosthesis or during its transportation through the trocar to the implantation site.
Thus, there remains the need for a prosthetic fabric comprising barbed naps, that can be used for manufacturing prostheses, such as for example abdominal wall reinforcements, capable of being conveyed within a channel such as that of a trocar, without damaging the barbs, and capable of being completely deployed, and preferably in an easy manner, once it has reached the implantation site in the body of the patient.
The present invention aims to remedy such a need.
A first aspect of the present invention relates to a prosthetic fabric comprising an arrangement of yarns that define at least first and second opposite faces for said fabric, said fabric comprising on at least said first face one or more barbs that protrude outwards relative to said first face, said fabric being covered, at least partly, on said second face with a layer made of a bioresorbable material, the outer surface of said layer being impenetrable by said barbs, characterized in that the barbs are, in addition, covered with a coating made of a water-soluble material.
Another aspect of the invention relates to a prosthetic fabric comprising an arrangement of yarns that define at least first and second opposite faces for said fabric, said fabric comprising on at least said first face one or more barbs that protrude outwards relative to said first face, said fabric being covered, at least partly, on said second face with a layer made of a bioresorbable material, the outer surface of said layer being impenetrable by said barbs, said impenetrable layer comprising at least a bioactive agent.
In the present application, by the fact that the outer surface of the layer is impenetrable to said barbs, it is understood that the outer surface of the layer is either non porous or is provided with micropores the size of which is less than the size of the barbs so that the barbs are not allowed to penetrate within the layer of bioresorbable material. In other words, when the barbs come in contact with the outer surface of the layer of bioresorbable material, for example when the fabric is rolled upon itself, then the barbs are stopped by the outer surface of the layer of bioresorbable material and do not enter this layer. As a consequence, as long as the layer of bioresorbable material is not bioresorbed, the barbs can not get entangled in the fabric, even if the fabric is rolled upon itself.
The impenetrable layer according to the prevent invention may be a microporous layer.
Another aspect of the present invention relates to a prosthetic fabric comprising an arrangement of yarns that define at least first and second opposite faces for said fabric, said fabric comprising on at least said first face one or more barbs that protrude outwards relative to said first face, said fabric being covered, at least partly, on said second face with a microporous layer made of a bioresorbable material characterized in that the barbs are, in addition, covered with a coating made of a water-soluble material.
In the present application, the expression “microporous layer” is understood to mean a layer having an outer surface which is free of pores with a size strictly greater than 300 μm, in other words free of pores for which at least one diameter is strictly greater than 300 μm. Thus, the outer surface of the microporous layer of the fabric according to the invention may not comprise pores at all or else may comprise pores whose average size is of the order of one nanometre; alternatively, the outer surface of the microporous layer of the fabric according to the invention comprises pores whose maximum size is less than or equal to 300 μm, for example less than or equal to 150 μm.
In the case where the outer surface of the microporous layer of the fabric according to the invention comprises pores, the average size of these pores may preferably vary from 10 to 150 μm, for example from 20 to 150 μm: in such a case, the microporous layer of the fabric according to the invention may also comprise such pores in its thickness: such a microporous layer can promote cell colonization.
In the case where the outer surface of the microporous layer of the fabric according to the invention does not comprise pores, it preferably has a substantially smooth outer surface: in such a case the microporous layer of the fabric according to the invention may form a temporary barrier to macromolecules and to cells. For example, the non-porous layer may form a film.
In the present application, the term “biocompatible”, is understood to mean that the materials having this property can be implanted in the body of animals or of man.
In the present application, the term “bioresorbable” or “biodegradable” is understood to mean that the materials having this property are absorbed and/or degraded by the tissues or washed from the implantation site and disappear in vivo after a certain time, which may vary, for example, from a few hours to a few months, depending on the chemical nature of the materials.
Due to the presence of the impenetrable, in particular microporous, layer, the prosthetic fabric according to the invention may be wound around on itself without the barbs becoming entangled in the body of the fabric, that is to say in the part of the fabric between the two opposite faces of the fabric. The impenetrable, in particular microporous, layer prevents the barbs of the prosthetic fabric from fastening to the fabric, especially when the fabric is wound around on itself in order to be inserted into a trocar. Thus, when the prosthetic fabric according to the invention is wound around on itself, the barbs are in contact with the impenetrable, in particular microporous, layer, in particular with the outer surface of the latter, and are not damaged. Furthermore, due to the fact that the barbs do not become entangled in the fabric, the prosthetic fabric according to the invention is capable of being completely deployed once it has reached the implantation site in the body of the patient.
In the present application, the impenetrable, in particular microporous, layer may also retard or prevent the tissue growth of the surrounding tissues, thus acting as a barrier to post-operative tissue adhesions and prevent the formation of undesired scar tissue.
In one embodiment of the invention, the impenetrable, in particular microporous, layer is continuous, and completely covers said second face.
In one embodiment of the invention, said bioresorbable material comprises at least one collagen compound.
The expression “collagen compound” is understood in the sense of the present application to mean collagen which has at least partially lost its helical structure by heating or by any other method, or gelatin. The term “gelatin” here includes commercial gelatin made from collagen which has been denatured by heating and in which the chains have been at least partially hydrolysed and which has a molar mass of less than around 100 kDa.
In one embodiment of the invention, said collagen compound comprises oxidized collagen. Alternatively or in combination, said collagen compound comprises gelatin.
In one embodiment of the invention, said bioresorbable material comprises a hydrophilic macromolecular additive chosen from polyalkylene glycols, such as polyethylene glycol or polypropylene glycol, polysaccharides, such as starch, dextran and/or derivatives of cellulose, oxidized polysaccharides, mucopolysaccharides, and mixtures thereof. For example, said hydrophilic macromolecular additive is a polyethylene glycol having a molar mass of 4000 daltons (PEG 4000).
In embodiments of the invention, said bioresorbable material comprises at least one polyvinyl alcohol.
In embodiments of the invention, said bioresorbable material comprises at least one glycerol.
In embodiments of the invention, the impenetrable layer comprises at least one bioactive agent. The impenetrable layer may act as media for the release of one or more bioactive agents.
In embodiments of the invention, the barbs are, in addition, covered with a coating made of a water-soluble biocompatible material.
The expression “water-soluble material” is understood in the sense of the present application to mean a material capable of dissolving in an aqueous composition such as water or biological fluids, for example at ambient temperature, either approximately at a temperature of around 20 to 25° C., or at any higher temperature and in particular at the temperature of the human body, in other words at a temperature of around 37° C.
Preferably, the water-soluble material of the fabric according to the invention is in set or solid form at a temperature less than or equal to 35° C., when it is not in contact with an aqueous composition.
In general, the material that covers the barbs, due to its water-soluble nature, has a smooth surface at a temperature of less than or equal to 25° C.: thus, when a barb covered with water-soluble material comes into contact with another barb covered with water-soluble material, they slide over one another and do not put up any resistance.
Thus, in embodiments of the invention, the prosthetic fabric is covered, on its second face, with an impenetrable, for example microporous, layer made of a bioresorbable material and the barbs of its first face are covered with water-soluble material. When a prosthesis made of such a fabric is wound around on itself in order to make it slide into a trocar, the barbs are doubly protected: not only do they slide over the outer surface of the impenetrable, for example microporous, layer but they do not hook onto one another: they slide over one another and they are easily separated from one another as soon as the prosthesis is released from the walls of the trocar in the implantation site: the prosthesis is then easily deployed before all of the water-soluble material covering the barbs is completely dissolved.
When the fabric according to the invention is brought into contact with water or biological fluids, in particular at the temperature of the human body, i.e. around 37° C. at the implantation site, the material covering the barbs dissolves little by little and thus detaches from the barbs. The time necessary for the solubilization of all of the water-soluble material covering the barbs and the presence of the impenetrable, for example microporous, layer made of a bioresorbable material make it possible to deploy the prosthesis easily. Once the barbs are no longer covered, they can again play their role of fastening, either to another prosthetic fabric, or within a biological tissue, such as for example the abdominal wall.
Furthermore, this necessary solubilization time, of the order of a few seconds to a few minutes, also allows the surgeon to position the prosthesis, moving it if necessary, and this being easy since, as the water-soluble material is not yet completely dissolved, the barbs slide with respect to the surrounding tissues and do not yet fasten the prosthesis as they will do once they are completely free of the coating made of the water-soluble material.
In embodiments of the invention, said water-soluble material is biodegradable.
In embodiments, said water-soluble material is chosen from polyethylene glycols (PEGs), polyvinyl acetates (PVAcs), collagen, gelatin, polyglucuronic acid, hyaluronic acid, carboxymethyl cellulose, cellulose ethers, chitosan and mixtures thereof.
For example, said water-soluble material is a polyethylene glycol having a molar mass of less than or equal to 40 000 Da, preferably less than or equal to 20 000 Da. For example, said molar mass may vary from 1000 to 20 000 Da. The polyethylene glycols having such molar masses are particularly biodegradable.
In embodiments, said water-soluble material comprises at least one polyethylene glycol having a molar mass of around 1000 Da. Such a polyethylene glycol enables an improved solubilization.
In embodiments, said water-soluble material comprises at least one bioactive agent.
The impenetrable layer and/or the water-soluble material may act as media for the release of one or more bioactive agents.
In embodiments, both the impenetrable layer and the water-soluble material comprise each a bioactive agent. The bioactive agents of the impenetrable layer and of the water_soluble material may be identical or different. In embodiments, after implantation of the prosthetic fabric, the water-soluble material will be dissolved in the biological fluids before the entire bioresorption of the impenetrable layer. In consequence, such embodiments may be useful for releasing in the body of the patient one or several bioactive agents in a sequential manner: for example, a first bioactive agent initially present in the water-soluble material will be released rapidly together with the dissolution of the water-soluble material in the biological fluids, for a specific bioactive effect, and a second bioactive agent, initially present in the impenetrable layer, will be released later on and possibly during a longer time for a second bioactive effect. In case the same bioactive agent is present in both the water-soluble material and the impenetrable layer, then a first shock effect may be obtained with the dissolution of the water-soluble material, and then a more prolonged effect may be obtained during the progressive bioresorption of the impenetrable layer.
Another aspect of the present invention relates to a process for covering a prosthetic fabric comprising an arrangement of yarns that define first and second faces for said fabric, said fabric comprising, over at least said first face, one or more barbs that protrude outwards relative to said first face, characterized in that it comprises the following steps:
Another aspect of the present invention relates to a process for covering a prosthetic fabric comprising an arrangement of yarns that define first and second faces for said fabric, said fabric comprising, over at least said first face, one or more barbs that protrude outwards relative to said first face, characterized in that it comprises the following steps:
In embodiments, during step c°), a second layer of solution is applied to the partially gelled layer, before the application of the second face of the fabric.
In another embodiment, during step c°), a layer of a second solution of bioresorbable material is applied to the partially gelled layer, before the application of the second face of the fabric, the composition of said second solution of bioresorbable material being different from the solution obtained in a°). For example, said second solution may comprise the same bioresorbable material as the solution obtained in a°) but in different proportions. Such an embodiment makes it possible to obtain a prosthetic fabric covered on its second face with a film having good elasticity properties.
In embodiments, the prosthetic fabric obtained in step c°) is freeze-dried for a duration ranging from 20 to 60 hours. Such an embodiment makes it possible, for example, to obtain a prosthetic fabric covered on its second face with a microporous layer having pores that have a size ranging, for example, from 20 to 120 μm.
In embodiments, the two steps i) and ii) below are added, steps i) and ii) being carried out in any order relative to steps a°) and c°) described above:
In one embodiment of the process according to the invention, step ii) is carried out using a roll. Thus, the composition is uniformly spread over the roll then onto the barbs over which the roll is applied.
Another aspect of the invention relates to a prosthesis for the treatment of hernias, characterized in that it is manufactured from a fabric as described above or from a fabric obtained by the process as described above.
The present invention will now be described in greater detail with the aid of the following description and appended figures in which:
According to the present application, the expression “prosthetic fabric” is understood to mean any fabric obtained by an arrangement or an assembly of biocompatible yarns, fibres, filaments and/or multifilaments, such as a knitting, weaving, braiding or non-woven arrangement or assembly. The arrangement of the yarns of the fabric according to the invention defines at least two opposite faces, a first face and a second face. The prosthetic fabric according to the invention also comprises barbs that protrude from at least its first face. These barbs may protrude from said first face substantially perpendicular to the plane of said face or alternatively along one or more planes inclined relative to the plane of said face. These barbs are intended to function as fastening means, either by becoming entangled in one or more arrangements of yarns, fibres, filaments and/or multifilaments of another prosthetic fabric, or by anchoring to the biological tissues, such as for example an abdominal wall.
The barbs of the prosthetic fabric according to the invention may be formed from yarns, for example, hot-melt monofilament yarns directly resulting from the arrangement of yarns forming the fabric. Such fabrics and barbs and also their manufacturing process are, for example, described in applications WO 01/81667, DE 198 32 634 or else in U.S. Pat. Nos. 6,596,002, 5,254,133.
In such cases, for example, the barbs are formed from monofilament yarns made of polylactic acid.
Alternatively, the barbs of the prosthetic fabric according to the invention may be any hook produced from any biocompatible material, attached to the arrangement of yarns forming said fabric, whether these hooks were incorporated into said fabric during the manufacture (braiding, knitting, weaving, etc.) of said arrangement of yarns or were added afterwards.
Preferably, the barbs have the shape of a rod surmounted by a head: the average size of the heads of the barbs in general varies from 300 μm to 500 μm.
The yarns, or fibres or filaments and/or multifilaments forming the arrangement of yarns of the fabric according to the invention may be produced from any biodegradable or non-biodegradable biocompatible material. Thus, the biodegradable materials suitable for the yarns of the fabric of the present invention may be chosen from polylactic acid (PLA), polyglycolic acid (PGA), oxidized cellulose, polycaprolactone (PCL), polydioxanone (PDO), trimethylene carbonate (TMC), polyvinyl alcohol (PVA), polyhydroxyalkanoates (PHAs), polyamides, polyethers, copolymers of these compounds and mixtures thereof. The non-biodegradable materials suitable for the yarns of the fabric of the present invention may be chosen from polyethylene terephthalate (PET), polyamides, aramids, expanded polytetrafluoroethylene, polyurethane, polyvinylidene difluoride (PVDF), polybutylesters, PEEK (polyetheretherketone), polyolefins (such as polyethylene or polypropylene), copper alloys, silver alloys, platinum, medical grades of steel such as medical grade stainless steel, and combinations thereof.
In order to prepare a fabric according to the invention, a prosthetic fabric is generally provided comprising an arrangement of yarns that define at least two faces for said fabric, said fabric comprising, on at least one of its faces, one or more barbs that protrude outwards relative to said face: such fabrics may be prepared, for example, as described in WO 01/81667.
Fabrics with barbs that are suitable for the present invention are also available commercially from the company Sofradim Production under the trade name Parietex® Progrip or else Parietene® Progrip.
The prosthetic fabric according to the invention is at least partly covered on its second face, that is to say on its face opposite the face comprising the barbs, with an impenetrable, for example microporous, layer made of a bioresorbable material. The impenetrable, for example microporous, layer of the fabric according to the invention is produced from a solution comprising said bioresorbable material.
Any natural or synthetic biocompatible and bioresorbable material may be used for preparing the impenetrable, for example microporous, layer. It is understood that any combination of natural and synthetic biocompatible and resorbable materials may be used. The techniques for forming the impenetrable, for example microporous, layers from such materials are known to a person skilled in the art, for example, non-limitingly, casting, moulding and similar techniques.
In the present application, synthetic materials may be used for preparing the impenetrable, for example microporous, layer of the fabric according to the invention. Examples of suitable synthetic materials include, non-limitingly, polylactic acid, polyglycolic acid, polyhydroxybutyrate acid, polyesters, polyethylene glycols, polyvinyl alcohols, polydioxanones, polycaprolactone, glycerols, polyamino acids, polytrimethylene carbonates, copolymers, block copolymers and/or homopolymers of these compounds, and mixtures thereof. As a synthetic material suitable for the present invention, mention may be made of the copolymer of polyvinyl alcohol (PVA) and of polyethylene glycol (PEG) sold under the trade name Kollicoat® IR by BASF.
In the present application, natural biological polymers may be used to form the impenetrable, for example microporous, layer of the fabric according to the invention. Suitable materials include, non-limitingly, collagen, gelatin, fibrin, fibrinogen, elastin, keratin, albumin, hydroxypropyl methyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, carboxyethyl cellulose, carboxymethyl cellulose, and mixtures thereof. In addition, the natural biological polymers may be combined with one or more of the synthetic materials described above in order to form the impenetrable, for example microporous, layer of the fabric according to the invention.
According to one embodiment of the invention, the bioresorbable material is chosen from collagen compounds, hydrophilic macromolecular compounds, polyvinyl alcohols, glycerols and mixtures thereof.
According to one embodiment of the fabric according to the invention, the bioresorbable material of the impenetrable, for example microporous, layer comprises at least one collagen compound.
In such an embodiment of the invention, an aqueous solution of a collagen compound is used to form the impenetrable, for example microporous, layer of the present invention. The expression “collagen compound” is understood in the sense of the present application to mean collagen which has at least partially lost its helical structure by heating or by any other method, or gelatin. The term “gelatin” here includes commercial gelatin made from collagen which has been denatured by heating and in which the chains have been at least partially hydrolysed and which has a molecular weight of less than around 100 kDa. The collagen compound used may be formed from hydrolysed collagen, composed of a chains and having a molecular weight close to around 100 kDa. In the context of the present invention, the expression “α chains” is understood to mean intact a chains or fragments produced by the loss of a small number of amino acids. The term “unhydrolysed” is understood here to mean that less than 10% of the collagen chains have a molecular weight of less than around 100 kDa. If heating is used to denature the helical structure of the collagen, the heating must be moderate and carried out under conditions arranged in order to avoid the degradation, by hydrolytic cleavage, of the gelatin thus formed.
The collagen possibly being used in the context of the present application may be of human or animal origin, and/or a mixture of the two, such as for example type I porcine or bovine collagens, type I or type III human collagens, and/or mixtures of the latter. Native collagen may be used, in acid solution or after conversion, in order to eliminate the telopeptides by pepsin digestion.
In one embodiment of the invention, the collagen compound comprises oxidized collagen. In order to obtain such an oxidized collagen, the collagen may be modified by oxidative cleavage using any technique known to a person skilled in the art including, non-limitingly, the use of periodic acid or one of its salts as described by Tardy et al. in U.S. Pat. No. 4,931,546, the whole of the content being incorporated therefore as reference. The technique described in this document comprises the mixing of collagen in acid solution with a solution of periodic acid or one of its salts at a concentration ranging from around 5×10−3M to around 10−1M, and at a temperature ranging from around 10° C. to around 25° C., for around 10 minutes to around 72 hours. This method makes it possible to oxidize hydroxylysine and the sugars of collagen, thus creating reactive sites, aldehydes, without crosslinking the collagen thus converted. The oxidation of the collagen, thus described, makes it possible to obtain a controlled and moderate crosslinking in the collagen material, under suitable conditions. In other embodiments of the invention, the oxidative cleavage may be obtained by other means in order to obtain a controlled and moderate crosslinking, for example, but non-limitingly, β or γ irradiation. In other embodiments of the invention, the oxidative cleavage may be provided by other reactants that allow a controlled and moderate crosslinking, for example, and non-limitingly, to chemical reactants at appropriate, low and non-toxic doses.
In other embodiments of the invention, the degree of crosslinking of the collagen may be increased by any technique known to a person skilled in the art so as to adjust the degradation time of the impenetrable, for example microporous, layer as desired. The expression “moderate crosslinking” is understood in the sense of the present application to mean that the impenetrable, for example microporous, layer is at least 90% degraded (as measured by the residual weight) at the end of around one month after implantation. The expression “high crosslinking” is understood in the sense of the present application to mean that the impenetrable, for example microporous, layer is at least 90% degraded (as measured by the residual weight) at the end of around three months after implantation. The expression “very high crosslinking” is understood in the sense of the present application to mean that the impenetrable, for example microporous, layer is at least 90% degraded (as measured by the residual weight) at the end of around two years after implantation.
In the present application, a solution of oxidized collagen as defined above may be used to form the impenetrable, for example microporous, layer, having a collagen concentration ranging from around 5 g/l to around 50 g/l, preferably between around 10 g/l to around 35 g/l.
In the present application, the solution of oxidized collagen may be heated, for example at a temperature above 37° C. approximately, for example at a temperature ranging from around 40° C. to around 50° C., for at least around one hour, in order to at least partially denature the helical structure of the collagen. Other physical or chemical techniques for denaturing the collagen include, for example, non-limitingly, ultrasonic treatment or the addition of chaotropic agents.
In one embodiment of the invention, the collagen compound comprises gelatin. In such an embodiment, a gelatin solution as defined above may be used to form the impenetrable, for example microporous, layer, having a gelatin concentration ranging from around 5 g/l to around 50 g/l, preferably between around 25 g/l to around 35 g/l.
In one embodiment of the invention, the hydrophilic macromolecular compounds are chosen from polyalkylene glycols, such as polyethylene glycol or polypropylene glycol, polysaccharides, such as starch, dextran and/or derivatives of cellulose, oxidized polysaccharides, mucopolysaccharides, and mixtures thereof. For example, the hydrophilic macromolecular additive is a polyethylene glycol having a molar mass of 4000 daltons.
In one embodiment of the invention, one or more hydrophilic macromolecular compounds which are chemically inert with the collagen compound may be added to the solution in order to form the impenetrable, for example microporous, layer.
The macromolecular compound may have a molar mass ranging above around 3000 daltons, preferably between around 3000 and around 20,000 daltons. Suitable hydrophilic macromolecular compounds include, but in a non-limiting manner, polyalkylene glycols (such as polyethylene glycol, polypropylene glycol), polysaccharides (such as starch, dextran and/or derivatives of cellulose), oxidized polysaccharides, mucopolysaccharides, and mixtures thereof.
In the present application, polyethylene glycol 4000 (4000 corresponding to the molar mass) may be added as a hydrophilic macromolecular compound. The concentration of hydrophilic macromolecular compound may be from around 2 to 10 times lower than the concentration of the collagen compound in the solution for preparing the impenetrable, for example microporous, layer. Optionally, the hydrophilic macromolecular compound may be removed by diffusion through the impenetrable, for example microporous, layer in a few hours to a few days.
In one embodiment of the invention, the bioresorbable material comprises at least one glycerol. For example, the bioresorbable material comprises at least one collagen compound and at least one glycerol. For example, the bioresorbable material comprises at least one collagen compound, at least one glycerol and at least one hydrophilic macromolecular compound, for example polyethylene glycol 4000.
In the present application, the glycerol may be used in the solution of the collagen compound in order to form the impenetrable, for example microporous, layer. The glycerol concentration in the solution of the collagen compound may be from around 2 to around 10 times lower than the concentration of the collagen compound, preferably less than one third approximately of the concentration of the collagen compound in the solution for preparing the impenetrable, for example microporous, layer.
In the present application, the term “concentration” is understood to mean weight per volume concentrations.
In the present application, the initial concentrations, in the solution for preparing the impenetrable, for example microporous, layer, of the collagen compound, or of the hydrophilic macromolecular compound(s), in particular of polyethylene glycol 4000, and of the glycerol may range from around 2% to 10% for the collagen compound, from around 0.6% to 4% for the hydrophilic macromolecular compound(s) and from around 0.3% to around 2.5% for the glycerol, respectively.
The solution used to form the impenetrable, for example microporous, layer may be prepared by adding the collagen compound, the hydrophilic macromolecular compound(s) and the glycerol to water or to a water/alcohol, for example ethanol, mixture at a temperature ranging from around 30° C. to around 50° C. The solution may be neutralized to a neutral pH in order to avoid hydrolysing the collagen compound by heating and in order to obtain a film having a physiological pH while enabling the pre-crosslinking of the collagen compound if the mixture contains oxidized collagen as indicated above.
In one embodiment of the invention, the bioresorbable material comprises at least one polyvinyl alcohol.
In the present application, a solution of polyvinyl alcohol may be used to form the impenetrable, for example microporous, layer.
Polyvinyl alcohols suitable for the present application have, for example, properties that enable them to be bioresorbed in less than a few days.
Polyvinyl alcohols suitable for the present application have, for example, a degree of hydrolysis between around 80% and around 99%, preferably between around 90% and around 99%.
Polyvinyl alcohols suitable for the present application have, for example, a molar mass of less than around 200,000 daltons, preferably of less than around 50,000 daltons.
Polyvinyl alcohols suitable for the present application may be a mixture of polyvinyl alcohols having different characteristics, but corresponding to the preferences described above, in terms of degree of hydrolysis and molar masses.
In the present application, a solution of polyvinyl alcohol as defined above may be used to form the impenetrable, for example microporous, layer, having a polyvinyl alcohol concentration ranging from around 20 g/l to around 200 g/l, preferably between around 50 g/l to around 100 g/l.
In one embodiment of the invention, the bioresorbable material comprises at least one polyvinyl alcohol and at least one glycerol.
In the present application, the glycerol may be used in the polyvinyl alcohol solution in order to form the impenetrable, for example microporous, layer. The glycerol concentration in the polyvinyl alcohol solution may be from around 2 to around 10 times lower than the polyvinyl alcohol concentration, preferably less than one third approximately of the polyvinyl alcohol concentration.
In the present application, the impenetrable, for example microporous, layer made from polyvinyl alcohol is, for example, bioresorbed between around a few minutes and around a few days.
In the present application, the microporous layer may be obtained from a solution resulting from the mixture of the collagen compound and of polyvinyl alcohol.
In one embodiment of the invention, the bioresorbable material comprises at least one collagen compound and at least one polyvinyl alcohol.
In the present application, the polyvinyl alcohol concentration in the solution of the impenetrable, for example microporous, layer resulting from the mixture of the collagen compound and polyvinyl alcohol may be between 1 and 65% relative to the mass of the collagen compound, preferably between 20 and 50%.
In the present application, one or more hydrophilic macromolecular compounds which are chemically inert with the mixture of collagen compounds and polyvinyl alcohol may be added to the solution in order to form the impenetrable, for example microporous, layer.
The macromolecular compound may have a molar mass ranging above around 3000 daltons, preferably between around 3000 and around 20,000 daltons. Suitable hydrophilic macromolecular compounds include, but in a non-limiting manner, polyalkylene glycols (such as polyethylene glycol), polysaccharides (such as starch, dextran and/or cellulose derivatives), oxidized polysaccharides, mucopolysaccharides, and combinations of the latter.
In the present application, polyethylene glycol 4000 (4000 corresponding to the molar mass) may be added as a hydrophilic macromolecular compound. The concentration of the hydrophilic additives may be from around 2 to around 10 times lower than the total concentration of collagen compound and of polyvinyl alcohol. Optionally, the hydrophilic macromolecular compound may be removed by diffusion through the impenetrable, for example microporous, layer in a few hours to a few days.
Thus, in one embodiment of the invention, the bioresorbable material comprises at least one collagen compound, at least one polyvinyl alcohol and at least one hydrophilic macromolecular compound, for example polyethylene glycol 4000.
In the present application, the glycerol may be used in the solution of the mixture of collagen compound and polyvinyl alcohol in order to form the impenetrable, for example microporous, layer. The glycerol concentration in the solution of the mixture of collagen compound and polyvinyl alcohol may be from around 2 to around 10 times lower than the total concentration of the collagen compound and polyvinyl alcohol, preferably less than one third approximately of the total concentration of collagen component and polyvinyl alcohol.
Thus, in one embodiment of the invention, the bioresorbable material comprises at least one collagen compound, at least one polyvinyl alcohol and at least one glycerol. The bioresorbable material may also comprise copolymers of PVA and PEG sold under the trade name Kollicoat® IR by BASF.
The solution used to form the impenetrable, for example microporous, layer may be prepared by adding the collagen compound and the polyvinyl alcohol, the hydrophilic macromolecular additive(s), for example PEG 4000, the Kollicoat® IR and the glycerol to water or to a water/alcohol, for example ethanol, mixture at a temperature ranging from around 30° C. to around 50° C. The solution may be neutralized to a neutral pH in order to avoid hydrolysing the collagen compound by heating and in order to obtain a film having a physiological pH while enabling the pre-crosslinking of the collagen compound if the mixture contains oxidized collagen as indicated above.
In the present application, a bioactive agent may be added to the impenetrable, for example microporous, layer.
In the present application, the impenetrable, for example microporous, layer of the fabric according to the invention may act as a medium for the release of a bioactive agent.
In the present application, the expression “bioactive agent” is understood to mean a bioactive agent in its broadest sense, including any substance or mixture of substances which have a clinical use. Therefore, the bioactive agents may or may not have a pharmacological activity per se such as for example, non-limitingly, pigments or colorants. Alternatively, a bioactive agent may be any agent that provides a therapeutic or prophylactic effect, a compound that affects or participates in tissue growth, in cell growth, in cell differentiation, a compound that displays adhesion-preventing properties, a compound capable of causing a biological action such as an immune response or capable of playing a role in one or more biological processes. It is considered that the bioactive agent may be included in the solution that forms the impenetrable, for example microporous, layer, in any suitable form such as in the form of powder, liquid, gels and related forms.
The expression “bioactive agent” used here is used in its broadest sense and includes any substance or mixture of substances which have a clinical use. Consequently, the bioactive agents may or may not have a pharmacological activity per se such as for example pigments. Alternatively, a bioactive agent may be any agent that has a prophylactic or therapeutic effect, a compound which affects or participates in tissue growth, cell growth, and/or cell differentiation; a compound which may be capable of causing a biological action such as an immune respnse; or a compound which could play another role in one or more biological processes.
Any agent which can produce therapeutic benefits such as for example tissue repair or cell proliferation, which limits the risk of sepsis, may be added to the impenetrable, for example microporous, layer of the prosthetic fabric according to the invention. Such agents include, for example, fucans, dextrans, derivatives of dextrans, carrageenans, alginate, hyaluronic acid, keratin sulphate, keratan sulphate, dermatan sulphate, chitin, chitosan, combinations of these compounds and of their derivatives. For example, chitosan may be added to the impenetrable, for example microporous, layer of the prosthetic fabric according to the invention: chitosan is biodegradable, has good biocompatibility, has demonstrated haemostatic and bacteriostatic properties, and it also plays an important role in cell proliferation and tissue regeneration.
Examples of classes of bioactive agents which may be used according to the present application include antimicrobials, analgesics, adhesion-preventing agents, antipyretics, anaesthetics, anticonvulsants, antihistamines, anti-inflammatories, cardiovascular drugs, diagnostic agents, sympathomimetics, cholinornimetics, antimuscarinics, antispasmodics, hormones, growth factors, muscle relaxants, adrenergic antagonists, antineoplastics, immunogenic agents, immunosuppressors, digestive drugs, diuretics, steroids, lipids, narcotics, lipopolysaccharides, polysaccharides, polypeptides, proteins, hormones, enzymes and combinations thereof.
Antimicrobial agents suitable for the present invention may be included among quaternary amines (for example, triclosan also known under the name 2,4,4′-trichloro-2′-hydroxydiphenyl ether, or diallyldimethylammonium chloride also known as DADMAC, chlorhexidine and its salts (i.e. chlorhexidine acetate, chlorhexidine gluconate, chlorhexidine hydrochloride and chlorhexidine sulphate), silver and its salts (i.e. silver acetate, silver benzoate, silver carbonate, silver citrate, silver iodate, silver iodide, silver lactate, silver laurate, silver nitrate, silver oxide, silver palmitate, silver protein complex and silver sulphadiazine), polymyxin, tetracycline, aminoglycosides, such as tobramycin and gentamicin, rifampicin, bacitracin, neomycin, chloramphenicol, miconazole, quinolones such as oxolinic acid, norfloxacin, nalidixic acid, pefloxacin, enoxacin and ciprofloxacin, penicillins such as oxacillin and pipracil, nonoxynol-9, fusidic acid, cephalosporines, and combinations thereof. Antimicrobial proteins and peptides (i.e. bovine lactoferrin and lactoferricine B) may also be suitable as a bioactive agent according to the present application.
Other bioactive agents suitable for the present invention may be chosen from local anaesthetics; antisteroidal agents; parasympathomimetic agents; psychotherapeutic agents; tranquilizers; decongestants; hypnotic sedatives; steroids; sulphonamides; sympathomimetic agents; vaccines; vitamins; antimalarial drugs; anti-migraine agents; anti-parkinson agents such as L-dopa; antispasmodics; anticholinergic agents (e.g. oxybutynin); antitussives; bronchodilators; cardiovascular agents such as coronary vasodilators and nitroglycerin; alkaloids; analgesics; narcotics such as codeine, dihydrocodeinone, meperidine, morphine and the like; non-narcotics such as salicylates, aspirin, acetaminophen, D-propoxyphene and the like; opioid receptor antagonists such as naltrexone and naloxone; anti-cancer agents; anti-convulsants; anti-emetics; antihistamines; anti-inflammatory agents such as hormones (i.e. hydrocortisone, prednisolone, prednisone), non-hormonal agents (i.e. allopurinol, indomethacin, phenylbutazone and the like; prostaglandins and cytotoxic drugs; ostrogens; antibacterials; antibiotics; anti-fungals; anti-virals; anticoagulants; anticonvulsants; antidepressants; antihistamines; and immunological agents.
Other examples of bioactive biological agents suitable for the present invention include viruses and cells, peptides, polypeptides and proteins, analogues, muteins, and/or active fragments of these compounds, such as immunoglobulins, antibodies, beta-glycans, cytokines (e.g. lymphokines, monokines, chemokines), blood coagulation factors, haemopoietic factors, interleukins (IL-2, IL-3, IL-4, IL-6), interferons ([beta]-IFN, [alpha]-IFN and [gamma]-IFN), erythropoietin, nucleases, TNFs (tumor necrosis factors), CSFs (colony stimulating factors) (e.g. GCSF, GM-CSF, MCSF), insulin, anti-tumor agents and tumor suppressors, blood proteins, gonadotropins (e.g. FSH, LH, CG, etc.), hormones and hormone analogues (e.g. growth hormone), vaccines (e.g. tumour antigens, bacteria and viral antigens); somatostatin; antigens; blood coagulation factors; growth factors (e.g. nerve growth factor, insulin-like growth factor); protein inhibitors, protein antagonists and protein agonists; nucleic acids, such as antisense DNA and RNA molecules; oligonucleotides; and ribozymes.
In the present application, the impenetrable, for example microporous, layer may be prepared by first casting a solution of the bioresorbable material, such as for example, the collagen compound or the polyvinyl alcohol, intended to form said layer, and optionally containing the hydrophilic macromolecular compound(s) and glycerol and a bioactive agent, on a suitable and substantially flat inert support and by uniformly distributing the solution.
In the present application, a support is said to be inert if it does not react with the compounds of the solution of bioresorbable material as described above for the preparation of the impenetrable, for example microporous, layer of the fabric according to the invention and if it is not involved in the possible crosslinking processes. The inert supports suitable for the present invention may be made from hydrophobic materials such as for example, non-limitingly, polyvinyl chloride (PVC), polystyrene, or a material which may be detached and which will remain slightly adhesive and which may be easily separated from the fabric according to the invention at the moment of its surgical use.
In the present application, the inert support may consist of a film of polyvinyl chloride (PVC), onto which the solution of the impenetrable, for example microporous, layer is cast, the PVC being inert with respect to the bioresorbable material used for the impenetrable, for example microporous, layer of the fabric according to the invention.
In the present application, the density of the thin layer initially deposited in the form of solution on the inert support may be around 0.1 g of solution per cm2 to around 0.3 g per cm2. The solution of the impenetrable, for example microporous, layer may be cast at a temperature ranging from around 4° C. to around 30° C., preferably from around 18° C. to around 25° C. Once applied to the inert support, the solution of the impenetrable, for example microporous, layer is left under laminar flow until a gel is formed, until the solution is no longer fluid, for around 5 minutes to around 60 minutes. The gelling results from the cooling of the solution of the impenetrable, for example microporous, layer, for example when it contains collagen.
The second face, that is to say the one that does not comprise the barbs, of the prosthetic fabric is then applied to the at least partially gelled solution of the impenetrable, for example microporous, layer. Optionally, it is possible to apply a light pressure to the prosthetic fabric. This pressure must be light enough not to cause significant breaking of the portion of the layer of gelled solution in contact with the support, so as to maintain the integrity and continuity of the impenetrable, for example microporous, layer over its entire surface and to preferably cover the whole of the second face of the prosthetic fabric.
In the present application, before applying the prosthetic fabric, a second layer of solution may also be poured over the first. In one embodiment of the invention, the components of the solution used for the second layer are identical to those used for the first layer so as to obtain, at the end of the process, one and the same impenetrable, for example microporous layer. The density of the second thin layer deposited in the form of solution on the first layer may be around 0.1 g of solution per cm2 to around 0.3 g per cm2. The solution of the second layer may be cast as a temperature ranging from around 4° C. to around 30° C., for example from around 18° C. to around 25° C. Once applied to the support, the solution of the second microporous layer is left under laminar flow until a gel forms, until the solution is no longer fluid, for around 5 minutes to around 60 minutes. The gelling results from the cooling of the solution when it contains collagen. The prosthetic fabric is then applied to the gelled solution as indicated above in the context of the casting of a single thin layer.
In the present invention, the prosthetic fabric covered with the partially gelled impenetrable, for example microporous, layer may be dried in order to carry out the complete gelling of the impenetrable, for example microporous, layer. When the solution of the impenetrable, for example microporous, layer comprises oxidized collagen, the collagen is crosslinked during the drying process at a temperature of around 4° C. to around 35° C., preferably from around 18° C. to around 30° C. The whole assembly is dried under a sterile air flow.
After drying, the prosthetic fabric covered according to the invention may be separated from the inert support, cut to a defined size, if necessary, in order to manufacture a prosthesis, then packaged and sterilized using conventional techniques, such as for example, but non-limitingly, β irradiation (electronic irradiation), γ irradiation (irradiation with radioactive cobalt) or ethylene oxide treatment.
In embodiments of the invention, the barbs of the prosthetic fabric may be covered with a water-soluble material, before, during or after the process for covering the second face with the impenetrable, for example microporous, layer made of bioresorbable material.
In one embodiment, said water-soluble material is chosen from polyethylene glycols (PEGs), polyvinyl acetates (PVAcs), gelatin, polyglucuronic acid, hyaluronic acid, carboxymethyl cellulose, cellulose ethers, chitosan and mixtures thereof.
For example, said water-soluble material is a polyethylene glycol having a molar mass of less than or equal to 40 000 Da, preferably less than or equal to 20 000 Da. For example, said molar mass may vary from 1000 to 20 000 Da. The polyethylene glycols having such molar masses are particularly biodegradable.
In one embodiment, said water-soluble material comprises at least one polyethylene glycol having a molar mass of around 1000 Da. Such a polyethylene glycol permits an improved solubilization.
In embodiments, the water-soluble material comprises at least one bioactive agent. The bioactive agents that may be present in the water-soluble material may be chosen among the bioactive agents described above for the impenetrable layer.
Thus, in embodiments of the process according to the invention, the two steps i) and ii) below are added, steps i) and ii) being carried out in any order relative to steps a°) to c°) described above:
The composition comprising the water-soluble biocompatible material in the liquid state may be in liquid, viscous or else pasty form. For example, the composition has a consistency that enables it to be spread over the barbs, for example using a brush or else a roll, or that enables the barbs to be immersed within it. In one embodiment of the process according to the invention, step ii) is carried out using a roll. Thus, the composition is uniformly spread over the roll then onto the barbs over which the roll is applied.
In one embodiment of the process according to the invention, said composition is obtained by solubilization of said water-soluble material in water, optionally by heating said composition at the melting point of said water-soluble material.
In one such embodiment, once the layer of composition is applied to the barbs, the composition is left to dry, and optionally cool, until the layer of water-soluble material covering the barbs is in the set state, that is to say solid state.
In another embodiment of the process according to the invention, said composition is obtained by heating said water-soluble material alone, at a temperature above the melting point of said water-soluble material. In such an embodiment, once the layer of composition is applied to the barbs, the composition is left to cool until the layer of water-soluble material covering the barbs is in the set state, that is to say solid state.
In the present application, when the prosthetic fabric is obtained from materials that are sensitive to hydrolysis such as polyglycolic acid or polylactic acid, it is packaged under conditions that are sufficiently low in moisture in order to prevent its degradation during storage.
The prosthetic fabrics of the present invention are stable at ambient temperature. The thickness of the impenetrable, for example microporous, layer may be less than around 150 μm, preferably between around 30 μm and around 100 μm. The prosthetic fabrics of the present invention may be produced at a predetermined size or be produced in large dimensions in order to be able to be cut therefore to suitable sizes for the applications envisaged, for example manufacture of prostheses.
Such prostheses may be implanted using open surgery or laparoscopic surgery. When implanted by laparoscopic surgery, the prosthesis must be wound around itself, before its insertion into the trocar. The impenetrable, for example microporous, layer of the prosthetic fabric according to the invention prevents the barbs from fastening to the prosthetic fabric during the transport of the prosthesis through the trocar and its deployment at the implantation site.
Thus, when the surgeon wishes to implant a prosthesis formed from a fabric according to the invention, he can easily wind this prosthesis around itself by folding the face provided with covered barbs towards the inside or towards the outside. In both cases, during this winding, the barbs come into contact with the impenetrable, for example microporous, layer, in particular against its outer gelled surface which may be substantially smooth, against which they are stopped: thus, the barbs do not penetrate into the body of the fabric and they do not become entangled with the arrangement of yarns constituting the fabric. Furthermore, the barbs are protected from rubbing against the walls of the trocar or against any other exterior element of the environment.
Once the prosthesis is conveyed to the implantation site via the trocar, the prosthesis can be unwound and deployed easily since the barbs slide over the impenetrable, for example microporous, layer and do not put up any resistance to the deployment of the prosthesis.
The prosthesis is deployed and the impenetrable, for example microporous, layer comes, little by little, into contact with the surrounding biological tissues where it is gradually bioresorbed. The prosthesis may be fastened, either to another fabric, or to a biological wall, using the barbs, the latter not having been subjected to any damage during the transport of the prosthesis in the channel of the trocar and having retained their coupling properties. In embodiments where the barbs are covered by a water-soluble material, the barbs may be used to fasten the prosthetic fabric to another fabric or to a biological wall once the water-soluble material has dissolved.
The prosthesis of the present application may maintain all the unique and original properties of the barbed prosthetic fabric, such as its use in the reinforcement and repair of soft tissues and its attachment to the tissues to be reinforced via the barbs, even after it has been transported through a trocar and deployed, in laparoscopic surgery.
The following examples illustrate the invention.
A prosthetic fabric, having a size of 15×10 cm2 and comprising barbs as described in WO 01/81667 is provided. The barbs are produced from a monofilament yarn made of polylactic acid (PLA).
A schematic representation of a cross section of such a fabric is given in
A microporous layer, in the form of a film comprising oxidized collagen, is combined with this prosthetic fabric on the face 2b, the face opposite the face bearing the barbs, in the following manner:
1°) Preparation of the Solution of Bioresorbable Material in Order to Form the Microporous Layer:
The collagen used is type I porcine collagen, extracted from pork skin by solubilization at acid pH or by pepsin digestion, and purified by saline precipitation according to known techniques.
Preferably, the dry collagen fibres are obtained by precipitation of an acid solution of collagen by addition of NaCl, then the washing and the drying of the precipitate are carried out with aqueous solutions of acetone having an acetone concentration increasing from 80% to 100%.
Prepared from these collagen fibres is a 3% w/v collagen solution which is oxidized by periodic acid at the final concentration of 8 mM, at ambient temperature, according to Example 4 of document U.S. Pat. No. 6,596,304.
A sterile concentrated solution of PEG 4000 (polyethylene glycol having a molar mass of 4000 daltons, for example sold by Fluka under the trade name PEG 4000) and of glycerol (also sold by Fluka) is added to the oxidized collagen solution at the concentration of 3% w/v, so as to obtain a mixture containing PEG 4000 at the final concentration of 1% w/v and glycerol at the final concentration of 0.6% w/v. The pH of the solution is adjusted to 7.0 by adding a concentrated sodium hydroxide solution. The volume of the solution is then topped up with sterile water so as to obtain final concentrations of oxidized collagen, of PEG 4000 and of glycerol of 2.7% w/v, 0.9% w/v and 0.54% w/v, respectively.
2°) Covering Face 2b of the Prosthetic Fabric:
A portion of the solution obtained in 1°) is spread so as to form a thin first layer with a density of 0.095 g/cm2 over a flat hydrophobic inert support made of PVC or of polystyrene.
The surface of the first layer is then exposed to a flow of sterile air at ambient temperature, for between 5 and 60 minutes, in order to allow the solution to gel. The remaining solution is diluted to the concentration of 2% w/v with sterile water, then to the concentration of 1.75% with absolute ethanol. This solution is spread so as to form a thin second layer with a density of 0.045 g/cm2 and is applied to the first layer.
The surface of the second layer is again exposed to a flow of sterile air at ambient temperature, for between 5 and 60 minutes. The prosthetic fabric is then applied gently to the gelled layer of the solution obtained in 1°) formed from the first and second layers above. The whole assembly is exposed to a flow of sterile air, at ambient temperature, until complete evaporation is achieved, in around 18 hours.
A barbed prosthetic fabric is obtained which is covered on its face that does not comprise the barbs with a microporous layer in the form of a continuous film. The microporous layer is continuous and completely covers said second face.
The relative concentrations of collagen, of PEG and of glycerol are 3/1/0.6, w/w/w, in the microporous layer, after drying.
The prosthetic fabric thus covered on its second face with the microporous layer is then detached from the inert support. In this example, the film forming the microporous layer (itself formed from the first and second layers above) is substantially free of pores and its outer surface is substantially smooth.
A covered prosthetic fabric is manufactured in the same manner as in Example 1A above, except that a bioactive agent, is added to the solution prepared in Example 1A 1°).
A schematic representation of a cross section of such a fabric 5 according to the invention is given in
Moreover, the covered prosthetic fabric of the present example allows releasing a bioactive agent once the prosthetic fabric is implanted.
It is possible to manufacture prostheses for the treatment of hernias from the barbed fabric coated with a microporous layer as described in the present example, by cutting a rectangular or round shape, or a shape suitable for the anatomy of the organ to be treated, from said fabric.
The barbed fabric, coated with a microporous layer based on collagen, PEG 4000, glycerol and a bioactive agent as described in the present example, is particularly suitable for the manufacture of prostheses for the treatment of hernias via a coelioscopic technique. Indeed, such prostheses may be wound around themselves, barbs on the inside and/or on the outside and be conveyed in this manner into the channel of a trocar to the implantation site without risk of damaging the barbs. Furthermore, due to the presence of the microporous layer, the barbs, in particular the heads of these barbs, do not become entangled in the body of the fabric and do not hinder the deployment of the prosthesis once it is released from the trocar at the implantation site: once the prosthesis is unwound, the barbs, due to their coupling properties, may be used to fasten the prosthesis in the manner desired by the surgeon.
The prosthetic fabric covered as described above may be packed in a sterile double bag. It may be sterilized, preferably, by γ irradiation, at a dose ranging from 25 to 45 kGy. After sterilization, it is heated in an oven at 50° C. for around 48 hours. It is then stored at ambient temperature until it is used.
Covering the Barbs of the Prosthetic Fabric of Example 1A with a Water Soluble Material:
A prosthetic fabric as obtained in Example 1A is provided before being packed. The barbs of the fabric are covered with a coating made of a water-soluble material, for example according to the following method:
5 g of polyethylene glycol having a molar mass of 4000 (PEG 4000 from FLUKA) the melting point of which is between 53° C. and 59° C., is heated at 60° C. in order to obtain a homogeneous liquid. Alternatively, the polyethylene glycol of molar mass 4000 could be replaced by a mixture of polyethylene glycols having molar masses of 1000, 2000 and 4000 respectively.
The barbs of the prosthetic fabric are coated with the PEG 4000 in the liquid state using a brush or by immersing the barbs in the liquid PEG 4000 composition.
For example, if a brush is used, and as a function of the viscosity of the PEG 4000 composition, the coating may be carried out by several successive passes of brushes over the barbs.
The thus covered fabric is then left to cool at ambient temperature (at around 20° C.). The PEG 4000 composition sets and coats the barbs, covering them with a smooth solid coating.
A schematic representation of a cross section of such a fabric 5 according to the invention, the second face of which is covered with a microporous layer 6 made of a bioresorbable material (as described in Example 1A above) and the barbs of which are covered with a water-soluble material, is given in
Thus, the coating of the barbs with PEG 4000 reduces the coupling of the fabric and facilitates its handling.
It is possible to manufacture prostheses for the treatment of hernias from the fabric with barbs coated with polyethylene glycol as described in the present example, by cutting a rectangular or round shape, or a shape suitable for the anatomy of the organ to be treated, from said fabric.
The fabric as described in the present example is particularly suitable for the manufacture of prostheses for the treatment of hernias via coelioscopy. Indeed, such prostheses may be wound around themselves, with the barbs on the inside and/or on the outside and be thus transported in the channel of a trocar to the implantation site without risk of damaging the barbs. Furthermore, due to the fact of the presence of the microporous layer on the second face of the fabric and of the coating made of water-soluble material of the barbs, the barbs do not obstruct the deployment of the prosthesis once it has been released from the trocar at the implantation site.
Covering the Barbs of the Prosthetic Fabric of Example 1B with a Water Soluble Material:
Before packaging the prosthesis, the barbs of the prosthetic fabric of Example 1B are covered with a water soluble material in the same manner as described in Example 1C.
The same initial prosthetic fabric as in EXAMPLE 1A above and represented in
1°) Preparation of the Solution of Bioresorbable Material in Order to Form the Microporous Layer:
A sterile concentrated solution of PEG 4000 (polyethylene glycol having a molar mass of 4000 daltons, for example sold by Fluka under the trade name PEG 4000) and of glycerol (also sold by Fluka) is added to a solution of gelatin (obtained by acid hydrolysis or by alkaline hydrolysis, for example sold by Sigma) at the concentration of 3% w/v, so as to obtain a mixture containing PEG 4000 at the final concentration of 1% w/v and glycerol at the final concentration of 0.6% w/v. The pH of the solution is adjusted to 7.0 by adding a concentrated solution of sodium hydroxide. The volume of the solution is then topped up with sterile water so as to obtain final concentrations of gelatin, of PEG 4000 and of glycerol of 2.7% w/v, of 0.9% w/v and of 0.54% w/v, respectively.
2°) Covering of Face 2b of the Prosthetic Fabric:
The solution obtained in 1°) is spread so as to form a thin layer with a density of 0.133 g/cm2 on a flat hydrophobic inert support made of PVC or of polystyrene. The surface is then exposed to a flow of sterile air at ambient temperature for between 5 and 60 minutes, in order to allow the solution obtained in 1°) to gel. The second face 2b of the prosthetic fabric is then gently applied to the gelled layer of said solution. The whole assembly is exposed to a flow of sterile air, at ambient temperature, until complete evaporation is achieved, in around 18 hours.
A barbed prosthetic fabric is obtained which is covered on its face that does not comprise the barbs with a microporous layer in the form of a continuous film.
The relative concentrations of gelatin, of PEG and of glycerol are 3/1/0.6, w/w/w, in the non-porous layer, after drying.
The prosthetic fabric covered as described above is then detached from the inert support. As in the preceding example, the film forming the microporous layer is substantially free of pores and its outer surface is essentially smooth.
3°) Covering the Barbs with a Water Soluble Material:
The barbs are covered with a water soluble material using the same method as that described in Example 1C.
The covered prosthetic fabric thus obtained may be packed in a sterile double bag. It is then sterilized, preferably by γ irradiation, at a dose ranging from 25 to 45 kGy. It is then stored at ambient temperature until it is used, for example in order to manufacture a prosthesis.
The same initial prosthetic fabric as in EXAMPLE 1A above, described in
1°) Preparation of the Solution of Bioresorbable Material in Order to Form the Microporous Layer:
A solution of polyvinyl alcohol (PVA) (provided by Sigma Aldrich, in 87-89% hydrolysed form, Mw=31,000-50,000) is prepared at 8% w/v in solution by heating at 90° C., using a magnetic hot plate stirrer, 4% glycerol is added, then the solution is cooled to 40° C.
2°) Covering of Face 2b of the Prosthetic Fabric:
30 ml of the solution obtained in 1°) is cast on a 12 cm×17 cm silicone frame. The second face 2b of the prosthetic fabric is placed on said solution. After drying for around 10 hours under a laminar flow hood, the layer of solution is at least partially gelled and the prosthetic fabric thus covered is detached from the frame. A prosthetic fabric according to the invention is obtained, covered on its face that does not comprise the barbs with a microporous layer in the form of a PVA film. This PVA film is not soluble at ambient temperature but becomes so at 37° C. The PVA film thus obtained has a smooth outer surface that is free of pores, in particular free of pores having a size strictly greater than 300 μm.
3°) Covering the Barbs with a Water Soluble Material:
The barbs are covered with a water soluble material using the same method as that described in Example 1C.
The prosthetic fabric thus covered is packaged in sealed bags and is sterilized by β or γ irradiation or by EtO. After sterilization using ethylene oxide or via beta or gamma irradiation, the covered prosthetic fabric is heated in an oven at 50° C. for around 50 hours.
The thus coated covered prosthetic fabric makes it possible to produce prostheses which can easily be wound around themselves in order to be introduced into a trocar: by virtue of the presence of the microporous layer on the face that does not comprise the barbs and of the water-soluble material on the barbs, the latter do not become entangled with one another during the rolling up of the prosthesis. The unrolling and the positioning of the prosthesis on exiting the trocar are thus facilitated.
The same initial prosthetic fabric as in EXAMPLE 1A above, described in
1°) Preparation of Two Solutions of Bioresorbable Material in Order to Form the Microporous Layer:
a) a solution of oxidized collagen at 3.4% w/v and glycerol at 1.4% w/v is prepared as described in example 1.
b) a solution of polyvinyl alcohol (PVA) (provided by Sigma Aldrich, in 87-89% hydrolysed form, Mw=31,000-50,000) is prepared at 3.4% w/v in solution by heating at 90° C. using a magnetic hot plate stirrer, then the solution is cooled and is kept at 40° C.
c) 50% (w/w) of the PVA solution obtained in b) is mixed with 50% (w/w) of the oxidized collagen/glycerol solution obtained in a) in order to obtain a first film. After mixing the two compounds, the solution is neutralized at pH 7, using a 1M sodium hydroxide solution.
d) a solution is prepared composed of oxidized collagen, PVA and glycerol in the following proportions, given by weight: 2.7% of oxidized collagen, 0.35% of PVA and 0.35% of glycerol. Thus, this solution comprises the same components as the solution obtained in c), but in different proportions.
2°) Covering of Face 2b of the Prosthetic Fabric:
a) Obtaining a First Film:
30 ml of the solution obtained in 1° c.) are cast on a 12 cm×17 cm silicone frame. Gelling appears after 20 to 30 minutes at ambient temperature. A first film is obtained.
b) Obtaining a Second Film:
1 hour after the casting carried out in a), the solution obtained in 1° d) is cast over the first film. The gelling of this new layer appears after 20 to 30 minutes. Drying is carried out under a laminar flow hood at ambient temperature for around 10 to around 14 hours.
A prosthetic fabric according to the invention is obtained covered on its face that does not comprise the barbs with a microporous layer in the form of a two-layer film. The complete covering of the face that does not comprise the barbs is thus facilitated.
After sterilization using ethylene oxide, or via beta or gamma irradiation, the prosthetic fabric is heated in an oven at 50° C. for around 48 hours.
In wet form, the two-layer film obtained according to the present example does not exhibit delamination of the two superposed layers in an aqueous medium. Furthermore, this two-layer film exhibits good elasticity. The outer surface of this two-layer film is smooth and free of pores, in particular pores having a size strictly greater than 300 μm.
3°) Covering the Barbs with a Water Soluble Material:
The barbs are covered with a water soluble material using the same method as that described in Example 1C.
The same initial prosthetic fabric as in EXAMPLE 1A above and represented in
1°) Preparation of the Solution of Bioresorbable Material in Order to Form the Microporous Layer:
8 g of pork gelatin (supplier: Sigma Aldrich) are dissolved in 92 ml of a 5% w/v aqueous solution of glycerol. The gelatin solution is dissolved at 45° C. with magnetic stirring, then heated for 10 minutes at 50° C. 30 ml of the solution obtained is hot-cast in a 12 cm×17 cm box, and the face 2b of the prosthetic fabric is placed directly onto the solution. After gelling of the gelatin solution at ambient temperature, the boxes are freeze-dried for 20 hours. The prosthetic fabric covered with the layer of gelatin is easily removed from the box. The layer or membrane of gelatin has a microporous structure: the membrane, and for example its outer surface, has pores with a size that varies from 20 to 120 μm, but does not have pores with a size greater than 300 μm: a photo of this membrane taken with a scanning electron microscope is represented in
The unrolling and the positioning of a prosthesis made from such a fabric, on exiting the trocar, are thus facilitated.
2°) Covering the Barbs with a Water Soluble Material:
The barbs are covered with a water soluble material using the same method as that described in Example 1C.
Barbed fabrics coated with a microporous layer as described in Examples 1 to 5 above are particularly suitable for the manufacture of prostheses for the treatment of hernias via coelioscopy. Indeed, such prostheses may be wound around themselves, with the barbs on the inside and/or on the outside and be thus conveyed in the channel of a trocar to the implantation site without risk of entanglement or damaging of the barbs. Furthermore, due to the presence of the microporous layer and optionally of the water-soluble material on the barbs, the barbs do not become entangled in the body of the fabric and do not obstruct the deployment of the prosthesis once it is released from the trocar at the implantation site: once the prosthesis is unwound and optionally after dissolving of the water-soluble material, the barbs, by virtue of their coupling properties, may be used to fasten the prosthesis in the manner desired by the surgeon.
Covered prosthetic fabrics such as that described in examples 1C, 1 D and 2-5 are manufactured wherein the water soluble material used for covering the barbs further includes a bioactive agent.
Such a covered prosthetic fabric as described in Example 1D for which the water soluble material further includes a bioactive agent may be used for releasing in the body of the patient one or more bioactive agents in a sequential manner.
| Number | Date | Country | Kind |
|---|---|---|---|
| 0956039 | Sep 2009 | FR | national |
This application is a divisional of U.S. patent application Ser. No. 13/393,994, filed on Mar. 2, 2012, which is a National Stage Application of PCT/EP2010/0693062 under 35 USC § 371 (a) filed on Sep. 6, 2010, which claims benefit of and priority to French Patent Application No. 0956039 filed Sep. 4, 2009, the disclosures of each of the above-identified applications are hereby incorporated by reference in their entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 1187158 | Mcginley | Jun 1916 | A |
| 3118294 | Van Laethem | Jan 1964 | A |
| 3124136 | Usher | Mar 1964 | A |
| 3272204 | Artandi et al. | Sep 1966 | A |
| 3276448 | Kronenthal | Oct 1966 | A |
| 3320649 | Naimer | May 1967 | A |
| 3364200 | Ashton et al. | Jan 1968 | A |
| 3511904 | Griset | May 1970 | A |
| 3570482 | Shigeru et al. | Mar 1971 | A |
| 4006747 | Kronenthal et al. | Feb 1977 | A |
| 4060081 | Yannas et al. | Nov 1977 | A |
| 4173131 | Melton et al. | Nov 1979 | A |
| 4193137 | Heck | Mar 1980 | A |
| 4248064 | Odham | Feb 1981 | A |
| 4294241 | Miyata | Oct 1981 | A |
| 4307717 | Hymes et al. | Dec 1981 | A |
| 4338800 | Matsuda | Jul 1982 | A |
| 4374669 | MacGregor | Feb 1983 | A |
| 4476697 | Schafer et al. | Oct 1984 | A |
| 4487865 | Balazs et al. | Dec 1984 | A |
| 4500676 | Balazs et al. | Feb 1985 | A |
| 4511653 | Play et al. | Apr 1985 | A |
| 4527404 | Nakagaki et al. | Jul 1985 | A |
| 4591501 | Cioca | May 1986 | A |
| 4597762 | Walter et al. | Jul 1986 | A |
| 4603695 | Ikada et al. | Aug 1986 | A |
| 4631932 | Sommers | Dec 1986 | A |
| 4670014 | Huc et al. | Jun 1987 | A |
| 4709562 | Matsuda | Dec 1987 | A |
| 4748078 | Doi et al. | May 1988 | A |
| 4759354 | Quarfoot | Jul 1988 | A |
| 4769038 | Bendavid et al. | Sep 1988 | A |
| 4796603 | Dahlke et al. | Jan 1989 | A |
| 4813942 | Alvarez | Mar 1989 | A |
| 4841962 | Berg et al. | Jun 1989 | A |
| 4854316 | Davis | Aug 1989 | A |
| 4925294 | Geshwind et al. | May 1990 | A |
| 4931546 | Tardy et al. | Jun 1990 | A |
| 4942875 | Hlavacek et al. | Jul 1990 | A |
| 4948540 | Nigam | Aug 1990 | A |
| 4950483 | Ksander et al. | Aug 1990 | A |
| 4970298 | Silver et al. | Nov 1990 | A |
| 5002551 | Linsky et al. | Mar 1991 | A |
| 5147374 | Fernandez | Sep 1992 | A |
| 5162430 | Rhee et al. | Nov 1992 | A |
| 5171273 | Silver et al. | Dec 1992 | A |
| 5176692 | Wilk et al. | Jan 1993 | A |
| 5192301 | Kamiya et al. | Mar 1993 | A |
| 5196185 | Silver et al. | Mar 1993 | A |
| 5201745 | Tayot et al. | Apr 1993 | A |
| 5201764 | Kelman et al. | Apr 1993 | A |
| 5206028 | Li | Apr 1993 | A |
| 5217493 | Raad et al. | Jun 1993 | A |
| 5254133 | Seid | Oct 1993 | A |
| 5256418 | Kemp et al. | Oct 1993 | A |
| 5263983 | Yoshizato et al. | Nov 1993 | A |
| 5304595 | Rhee et al. | Apr 1994 | A |
| 5306500 | Rhee et al. | Apr 1994 | A |
| 5324775 | Rhee et al. | Jun 1994 | A |
| 5328955 | Rhee et al. | Jul 1994 | A |
| 5334527 | Brysk | Aug 1994 | A |
| 5339657 | Mcmurray | Aug 1994 | A |
| 5350583 | Yoshizato et al. | Sep 1994 | A |
| 5356432 | Rutkow et al. | Oct 1994 | A |
| 5368549 | Mcvicker | Nov 1994 | A |
| 5376375 | Rhee et al. | Dec 1994 | A |
| 5376376 | Li | Dec 1994 | A |
| 5383897 | Wholey | Jan 1995 | A |
| 5397331 | Himpens et al. | Mar 1995 | A |
| 5399361 | Song et al. | Mar 1995 | A |
| 5413791 | Rhee et al. | May 1995 | A |
| 5425740 | Hutchinson, Jr. | Jun 1995 | A |
| 5428022 | Palefsky et al. | Jun 1995 | A |
| 5433996 | Kranzler et al. | Jul 1995 | A |
| 5441491 | Verschoor et al. | Aug 1995 | A |
| 5441508 | Gazielly et al. | Aug 1995 | A |
| 5456693 | Conston et al. | Oct 1995 | A |
| 5456711 | Hudson | Oct 1995 | A |
| 5466462 | Rosenthal et al. | Nov 1995 | A |
| 5480644 | Freed | Jan 1996 | A |
| 5487895 | Dapper et al. | Jan 1996 | A |
| 5490984 | Freed | Feb 1996 | A |
| 5512291 | Li | Apr 1996 | A |
| 5512301 | Song et al. | Apr 1996 | A |
| 5514181 | Light et al. | May 1996 | A |
| 5522840 | Krajicek | Jun 1996 | A |
| 5523348 | Rhee et al. | Jun 1996 | A |
| 5536656 | Kemp et al. | Jul 1996 | A |
| 5543441 | Rhee et al. | Aug 1996 | A |
| 5565210 | Rosenthal et al. | Oct 1996 | A |
| 5567806 | Abdul-Malak et al. | Oct 1996 | A |
| 5569273 | Titone et al. | Oct 1996 | A |
| RE35399 | Eisenberg | Dec 1996 | E |
| 5593441 | Lichtenstein et al. | Jan 1997 | A |
| 5595621 | Light et al. | Jan 1997 | A |
| 5601571 | Moss | Feb 1997 | A |
| 5607474 | Athanasiou et al. | Mar 1997 | A |
| 5607590 | Shimizu | Mar 1997 | A |
| 5614587 | Rhee et al. | Mar 1997 | A |
| 5618551 | Tardy et al. | Apr 1997 | A |
| 5634931 | Kugel | Jun 1997 | A |
| 5639796 | Lee | Jun 1997 | A |
| 5665391 | Lea | Sep 1997 | A |
| 5667839 | Berg | Sep 1997 | A |
| 5681568 | Goldin et al. | Oct 1997 | A |
| 5686115 | Vournakis et al. | Nov 1997 | A |
| 5690675 | Sawyer et al. | Nov 1997 | A |
| 5695525 | Mulhauser et al. | Dec 1997 | A |
| 5697978 | Sgro | Dec 1997 | A |
| 5700476 | Rosenthal et al. | Dec 1997 | A |
| 5700477 | Rosenthal et al. | Dec 1997 | A |
| 5709934 | Bell et al. | Jan 1998 | A |
| 5716409 | Debbas | Feb 1998 | A |
| 5720981 | Eisinger | Feb 1998 | A |
| 5732572 | Litton | Mar 1998 | A |
| 5749895 | Sawyer et al. | May 1998 | A |
| 5752974 | Rhee et al. | May 1998 | A |
| 5766246 | Mulhauser et al. | Jun 1998 | A |
| 5766631 | Arnold | Jun 1998 | A |
| 5769864 | Kugel | Jun 1998 | A |
| 5771716 | Schlussel | Jun 1998 | A |
| 5785983 | Furlan et al. | Jul 1998 | A |
| 5800541 | Rhee et al. | Sep 1998 | A |
| 5814328 | Gunasekaran | Sep 1998 | A |
| 5833705 | Ken et al. | Nov 1998 | A |
| 5840011 | Landgrebe et al. | Nov 1998 | A |
| 5861034 | Taira et al. | Jan 1999 | A |
| 5863984 | Doillon et al. | Jan 1999 | A |
| 5869080 | Mcgregor et al. | Feb 1999 | A |
| 5871767 | Dionne et al. | Feb 1999 | A |
| 5876444 | Lai | Mar 1999 | A |
| 5891558 | Bell et al. | Apr 1999 | A |
| 5899909 | Claren et al. | May 1999 | A |
| 5906937 | Sugiyama et al. | May 1999 | A |
| 5910149 | Kuzmak | Jun 1999 | A |
| 5911731 | Pham et al. | Jun 1999 | A |
| 5916225 | Kugel | Jun 1999 | A |
| 5919232 | Chaffringeon et al. | Jul 1999 | A |
| 5919233 | Knopf et al. | Jul 1999 | A |
| 5922026 | Chin | Jul 1999 | A |
| 5931165 | Reich et al. | Aug 1999 | A |
| 5942278 | Hagedorn et al. | Aug 1999 | A |
| 5962136 | Dewez et al. | Oct 1999 | A |
| 5964782 | Lafontaine et al. | Oct 1999 | A |
| 5972022 | Huxel | Oct 1999 | A |
| RE36370 | Li | Nov 1999 | E |
| 5993844 | Abraham et al. | Nov 1999 | A |
| 5994325 | Roufa et al. | Nov 1999 | A |
| 5997895 | Narotam et al. | Dec 1999 | A |
| 6001895 | Harvey et al. | Dec 1999 | A |
| 6008292 | Lee et al. | Dec 1999 | A |
| 6015844 | Harvey et al. | Jan 2000 | A |
| 6039686 | Robert | Mar 2000 | A |
| 6042534 | Gellman et al. | Mar 2000 | A |
| 6042592 | Schmitt | Mar 2000 | A |
| 6043089 | Sugiyama et al. | Mar 2000 | A |
| 6051425 | Morota et al. | Apr 2000 | A |
| 6056688 | Benderev et al. | May 2000 | A |
| 6056970 | Greenawalt et al. | May 2000 | A |
| 6057148 | Sugiyama et al. | May 2000 | A |
| 6063396 | Kelleher | May 2000 | A |
| 6066776 | Goodwin et al. | May 2000 | A |
| 6066777 | Benchetrit | May 2000 | A |
| 6071292 | Makower et al. | Jun 2000 | A |
| 6077281 | Das | Jun 2000 | A |
| 6080194 | Pachence et al. | Jun 2000 | A |
| 6083522 | Chu et al. | Jul 2000 | A |
| 6120539 | Eldridge et al. | Sep 2000 | A |
| 6132765 | Dicosmo et al. | Oct 2000 | A |
| 6143037 | Goldstein et al. | Nov 2000 | A |
| 6153292 | Bell et al. | Nov 2000 | A |
| 6165488 | Tardy et al. | Dec 2000 | A |
| 6171318 | Kugel et al. | Jan 2001 | B1 |
| 6174320 | Kugel et al. | Jan 2001 | B1 |
| 6176863 | Kugel et al. | Jan 2001 | B1 |
| 6179872 | Bell et al. | Jan 2001 | B1 |
| 6197036 | Tripp et al. | Mar 2001 | B1 |
| 6197325 | Macphee et al. | Mar 2001 | B1 |
| 6197934 | Devore et al. | Mar 2001 | B1 |
| 6197935 | Doillon et al. | Mar 2001 | B1 |
| 6210439 | Firmin et al. | Apr 2001 | B1 |
| 6221109 | Geistlich et al. | Apr 2001 | B1 |
| 6224616 | Kugel | May 2001 | B1 |
| 6241768 | Agarwal et al. | Jun 2001 | B1 |
| 6258124 | Darois et al. | Jul 2001 | B1 |
| 6262332 | Ketharanathan | Jul 2001 | B1 |
| 6264702 | Ory et al. | Jul 2001 | B1 |
| 6267772 | Mulhauser et al. | Jul 2001 | B1 |
| 6277397 | Shimizu | Aug 2001 | B1 |
| 6280453 | Kugel et al. | Aug 2001 | B1 |
| 6287316 | Agarwal et al. | Sep 2001 | B1 |
| 6290708 | Kugel et al. | Sep 2001 | B1 |
| 6306424 | Vyakarnam et al. | Oct 2001 | B1 |
| 6312474 | Francis et al. | Nov 2001 | B1 |
| 6328686 | Robert | Dec 2001 | B1 |
| 6334872 | Termin et al. | Jan 2002 | B1 |
| 6383201 | Dong | May 2002 | B1 |
| 6391333 | Li et al. | May 2002 | B1 |
| 6391939 | Tayot et al. | May 2002 | B2 |
| 6408656 | Ory et al. | Jun 2002 | B1 |
| 6410044 | Chudzik et al. | Jun 2002 | B1 |
| 6413742 | Olsen et al. | Jul 2002 | B1 |
| 6428978 | Olsen et al. | Aug 2002 | B1 |
| 6436030 | Rehil | Aug 2002 | B2 |
| 6440167 | Shimizu | Aug 2002 | B2 |
| 6443964 | Ory et al. | Sep 2002 | B1 |
| 6447551 | Goldmann | Sep 2002 | B1 |
| 6447802 | Sessions et al. | Sep 2002 | B2 |
| 6448378 | Devore et al. | Sep 2002 | B2 |
| 6451032 | Ory et al. | Sep 2002 | B1 |
| 6451301 | Sessions et al. | Sep 2002 | B1 |
| 6454787 | Maddalo et al. | Sep 2002 | B1 |
| 6477865 | Matsumoto | Nov 2002 | B1 |
| 6479072 | Morgan et al. | Nov 2002 | B1 |
| 6500464 | Ceres et al. | Dec 2002 | B2 |
| 6509031 | Miller et al. | Jan 2003 | B1 |
| 6511958 | Atkinson et al. | Jan 2003 | B1 |
| 6514286 | Leatherbury et al. | Feb 2003 | B1 |
| 6514514 | Atkinson et al. | Feb 2003 | B1 |
| 6540773 | Dong | Apr 2003 | B2 |
| 6541023 | Andre et al. | Apr 2003 | B1 |
| 6548077 | Gunasekaran | Apr 2003 | B1 |
| 6554855 | Dong | Apr 2003 | B1 |
| 6559119 | Burgess et al. | May 2003 | B1 |
| 6566345 | Miller et al. | May 2003 | B2 |
| 6575988 | Rousseau | Jun 2003 | B2 |
| 6576019 | Atala | Jun 2003 | B1 |
| 6596002 | Therin et al. | Jul 2003 | B2 |
| 6596304 | Bayon et al. | Jul 2003 | B1 |
| 6599323 | Melican et al. | Jul 2003 | B2 |
| 6599524 | Li et al. | Jul 2003 | B2 |
| 6599690 | Abraham et al. | Jul 2003 | B1 |
| 6613348 | Jain | Sep 2003 | B1 |
| 6623963 | Mueller et al. | Sep 2003 | B1 |
| 6630414 | Matsumoto | Oct 2003 | B1 |
| 6638284 | Rousseau et al. | Oct 2003 | B1 |
| 6652594 | Francis et al. | Nov 2003 | B2 |
| 6653450 | Berg et al. | Nov 2003 | B1 |
| 6656206 | Corcoran et al. | Dec 2003 | B2 |
| 6660280 | Allard et al. | Dec 2003 | B1 |
| 6669735 | Pelissier | Dec 2003 | B1 |
| 6682760 | Noff et al. | Jan 2004 | B2 |
| 6685714 | Rousseau | Feb 2004 | B2 |
| 6706684 | Bayon et al. | Mar 2004 | B1 |
| 6706690 | Reich et al. | Mar 2004 | B2 |
| 6719795 | Bryan et al. | Apr 2004 | B1 |
| 6723335 | Moehlenbruck et al. | Apr 2004 | B1 |
| 6730299 | Tayot et al. | May 2004 | B1 |
| 6743435 | Devore et al. | Jun 2004 | B2 |
| 6755868 | Rousseau | Jun 2004 | B2 |
| 6773723 | Spiro et al. | Aug 2004 | B1 |
| 6790213 | Cherok et al. | Sep 2004 | B2 |
| 6790454 | Abdul et al. | Sep 2004 | B1 |
| 6800082 | Rousseau | Oct 2004 | B2 |
| 6833408 | Sehl et al. | Dec 2004 | B2 |
| 6835336 | Watt | Dec 2004 | B2 |
| 6852330 | Bowman et al. | Feb 2005 | B2 |
| 6869938 | Schwartz et al. | Mar 2005 | B1 |
| 6893653 | Abraham et al. | May 2005 | B2 |
| 6896904 | Spiro et al. | May 2005 | B2 |
| 6936276 | Spiro et al. | Aug 2005 | B2 |
| 6939562 | Spiro et al. | Sep 2005 | B2 |
| 6949625 | Tayot | Sep 2005 | B2 |
| 6966918 | Schuldt-Hempe et al. | Nov 2005 | B1 |
| 6971252 | Therin et al. | Dec 2005 | B2 |
| 6974679 | Andre et al. | Dec 2005 | B2 |
| 6974862 | Ringeisen et al. | Dec 2005 | B2 |
| 6977231 | Matsuda | Dec 2005 | B1 |
| 6988386 | Okawa et al. | Jan 2006 | B1 |
| 7025063 | Snitkin et al. | Apr 2006 | B2 |
| 7041868 | Greene et al. | May 2006 | B2 |
| RE39172 | Bayon et al. | Jul 2006 | E |
| 7098315 | Schaufler | Aug 2006 | B2 |
| 7175852 | Simmoteit et al. | Feb 2007 | B2 |
| 7192604 | Brown et al. | Mar 2007 | B2 |
| 7207962 | Anand et al. | Apr 2007 | B2 |
| 7214765 | Ringeisen et al. | May 2007 | B2 |
| 7226611 | Yura et al. | Jun 2007 | B2 |
| 7229453 | Anderson et al. | Jun 2007 | B2 |
| 7594921 | Browning | Sep 2009 | B2 |
| 7670380 | Cauthen, III et al. | Mar 2010 | B2 |
| 20010008930 | Tayot et al. | Jul 2001 | A1 |
| 20020052612 | Schmitt et al. | May 2002 | A1 |
| 20020077661 | Saadat | Jun 2002 | A1 |
| 20020087184 | Eder et al. | Jul 2002 | A1 |
| 20020095218 | Carr et al. | Jul 2002 | A1 |
| 20020116070 | Amara et al. | Aug 2002 | A1 |
| 20020133232 | Ricci et al. | Sep 2002 | A1 |
| 20030013989 | Obermiller et al. | Jan 2003 | A1 |
| 20030023316 | Brown et al. | Jan 2003 | A1 |
| 20030040809 | Goldmann et al. | Feb 2003 | A1 |
| 20030086975 | Ringeisen | May 2003 | A1 |
| 20030100954 | Schuldt-Hempe et al. | May 2003 | A1 |
| 20030100955 | Greenawalt et al. | May 2003 | A1 |
| 20030114937 | Leatherbury et al. | Jun 2003 | A1 |
| 20030133967 | Ruszczak et al. | Jul 2003 | A1 |
| 20030212460 | Darois et al. | Nov 2003 | A1 |
| 20030225355 | Butler | Dec 2003 | A1 |
| 20030232746 | Lamberti et al. | Dec 2003 | A1 |
| 20040034373 | Schuldt-Hempe et al. | Feb 2004 | A1 |
| 20040054406 | Dubson et al. | Mar 2004 | A1 |
| 20040059356 | Gingras | Mar 2004 | A1 |
| 20040101546 | Gorman et al. | May 2004 | A1 |
| 20040132365 | Therin et al. | Jul 2004 | A1 |
| 20040138762 | Therin et al. | Jul 2004 | A1 |
| 20040172048 | Browning | Sep 2004 | A1 |
| 20040215219 | Eldridge et al. | Oct 2004 | A1 |
| 20050002893 | Goldmann | Jan 2005 | A1 |
| 20050010078 | Jamiolkowski et al. | Jan 2005 | A1 |
| 20050010306 | Priewe et al. | Jan 2005 | A1 |
| 20050021058 | Negro | Jan 2005 | A1 |
| 20050043786 | Chu et al. | Feb 2005 | A1 |
| 20050058684 | Shanley et al. | Mar 2005 | A1 |
| 20050079201 | Rathenow et al. | Apr 2005 | A1 |
| 20050085924 | Darois et al. | Apr 2005 | A1 |
| 20050113849 | Popadiuk et al. | May 2005 | A1 |
| 20050113938 | Jamiolkowski et al. | May 2005 | A1 |
| 20050125077 | Harmon et al. | Jun 2005 | A1 |
| 20050137512 | Campbell et al. | Jun 2005 | A1 |
| 20050142161 | Freeman et al. | Jun 2005 | A1 |
| 20050148963 | Brennan | Jul 2005 | A1 |
| 20050149173 | Hunter et al. | Jul 2005 | A1 |
| 20050175659 | Macomber et al. | Aug 2005 | A1 |
| 20050228408 | Fricke et al. | Oct 2005 | A1 |
| 20050232979 | Shoshan | Oct 2005 | A1 |
| 20050244455 | Greenawalt | Nov 2005 | A1 |
| 20050267521 | Forsberg | Dec 2005 | A1 |
| 20050283256 | Sommerich et al. | Dec 2005 | A1 |
| 20050288691 | Leiboff | Dec 2005 | A1 |
| 20060094318 | Matsuda et al. | May 2006 | A1 |
| 20060135921 | Wiercinski et al. | Jun 2006 | A1 |
| 20060147501 | Hillas et al. | Jul 2006 | A1 |
| 20060167540 | Masters et al. | Jul 2006 | A1 |
| 20060167561 | Odar et al. | Jul 2006 | A1 |
| 20060216320 | Kitazono et al. | Sep 2006 | A1 |
| 20060252981 | Matsuda et al. | Nov 2006 | A1 |
| 20070031474 | Tayot et al. | Feb 2007 | A1 |
| 20070100432 | Case et al. | May 2007 | A1 |
| 20070156238 | Liao et al. | Jul 2007 | A1 |
| 20070161109 | Archibald et al. | Jul 2007 | A1 |
| 20070207186 | Scanlon et al. | Sep 2007 | A1 |
| 20070239265 | Birdsall | Oct 2007 | A1 |
| 20070244569 | Weber et al. | Oct 2007 | A1 |
| 20070280990 | Stopek | Dec 2007 | A1 |
| 20070297987 | Stad et al. | Dec 2007 | A1 |
| 20070299538 | Roeber | Dec 2007 | A1 |
| 20080086216 | Wilson et al. | Apr 2008 | A1 |
| 20080132922 | Buevich et al. | Jun 2008 | A1 |
| 20090004239 | Ladet et al. | Jan 2009 | A1 |
| 20090024151 | Shalaby et al. | Jan 2009 | A1 |
| 20090036997 | Bayon et al. | Feb 2009 | A1 |
| 20090192532 | Spinnler | Jul 2009 | A1 |
| 20100016872 | Bayon et al. | Jan 2010 | A1 |
| Number | Date | Country |
|---|---|---|
| 1317836 | May 1993 | CA |
| 19544162 | Apr 1997 | DE |
| 10019604 | Oct 2001 | DE |
| 10043396 | Jun 2002 | DE |
| 0194192 | Sep 1986 | EP |
| 0248544 | Dec 1987 | EP |
| 0276890 | Aug 1988 | EP |
| 0372969 | Jun 1990 | EP |
| 0544485 | Jun 1993 | EP |
| 0552576 | Jul 1993 | EP |
| 0614650 | Sep 1994 | EP |
| 0621014 | Oct 1994 | EP |
| 0625891 | Nov 1994 | EP |
| 0637452 | Feb 1995 | EP |
| 0705878 | Apr 1996 | EP |
| 0719527 | Jul 1996 | EP |
| 0774240 | May 1997 | EP |
| 0797962 | Oct 1997 | EP |
| 0827724 | Mar 1998 | EP |
| 0836838 | Apr 1998 | EP |
| 0895762 | Feb 1999 | EP |
| 0898944 | Mar 1999 | EP |
| 1017415 | Jul 2000 | EP |
| 1052319 | Nov 2000 | EP |
| 1055757 | Nov 2000 | EP |
| 1216717 | Jun 2002 | EP |
| 1216718 | Jun 2002 | EP |
| 0693523 | Nov 2002 | EP |
| 1315468 | Jun 2003 | EP |
| 1382728 | Jan 2004 | EP |
| 1484070 | Dec 2004 | EP |
| 1561480 | Aug 2005 | EP |
| 1782848 | May 2007 | EP |
| 2244853 | Apr 1975 | FR |
| 2257262 | Aug 1975 | FR |
| 2308349 | Nov 1976 | FR |
| 2453231 | Oct 1980 | FR |
| 2715405 | Jul 1995 | FR |
| 2724563 | Mar 1996 | FR |
| 2744906 | Aug 1997 | FR |
| 2766698 | Feb 1999 | FR |
| 2771622 | Jun 1999 | FR |
| 2779937 | Dec 1999 | FR |
| 2859624 | Dec 2005 | FR |
| 2863277 | Jun 2006 | FR |
| 2884706 | Apr 2008 | FR |
| 2924330 | Jun 2009 | FR |
| 2051153 | Jan 1981 | GB |
| H0332677 | Mar 1991 | JP |
| H05237128 | Sep 1993 | JP |
| H09137380 | May 1997 | JP |
| 8902445 | Mar 1989 | WO |
| 8908467 | Sep 1989 | WO |
| 9012551 | Nov 1990 | WO |
| 9206639 | Apr 1992 | WO |
| 9220349 | Nov 1992 | WO |
| 9311805 | Jun 1993 | WO |
| 9318174 | Sep 1993 | WO |
| 9417747 | Aug 1994 | WO |
| 9507666 | Mar 1995 | WO |
| 9518638 | Jul 1995 | WO |
| 9532687 | Dec 1995 | WO |
| 9603091 | Feb 1996 | WO |
| 9608277 | Mar 1996 | WO |
| 9609795 | Apr 1996 | WO |
| 9614805 | May 1996 | WO |
| 9641588 | Dec 1996 | WO |
| 9735533 | Oct 1997 | WO |
| 9835632 | Aug 1998 | WO |
| 9849967 | Nov 1998 | WO |
| 9905990 | Feb 1999 | WO |
| 9906079 | Feb 1999 | WO |
| 9906080 | Feb 1999 | WO |
| 9951163 | Oct 1999 | WO |
| 0016821 | Mar 2000 | WO |
| 0067663 | Nov 2000 | WO |
| 0115625 | Mar 2001 | WO |
| 0180773 | Nov 2001 | WO |
| 0181667 | Nov 2001 | WO |
| 0207648 | Jan 2002 | WO |
| 02078568 | Oct 2002 | WO |
| 03002168 | Jan 2003 | WO |
| 2004004600 | Jan 2004 | WO |
| 2004071349 | Aug 2004 | WO |
| 2004078120 | Sep 2004 | WO |
| 2004103212 | Dec 2004 | WO |
| 2005011280 | Feb 2005 | WO |
| 2005013863 | Feb 2005 | WO |
| 2005018698 | Mar 2005 | WO |
| 2005105172 | Nov 2005 | WO |
| 2006018552 | Feb 2006 | WO |
| 2006023444 | Mar 2006 | WO |
| 2007048099 | Sep 2010 | WO |
| Entry |
|---|
| Amid, P., “Lichtenstein tension-free hernioplasty: Its inception, evolution, and principles,” Hernia, 2004; pp. 1-7, 8, published online Sep. 2003. |
| Blondin, C. et al., “Inhibition of Complement Activation by Natural Sulfated Polysaccharides (Fucans) from Brown Seaweed,” Molecular Immuol., Mar. 1994, pp. 247-253, 31(4). |
| Blondin, C. et al., “Relationships between chemical characteristics and anticomplementary activity of fucans,” Biomaterials, Mar. 1996, pp. 597-603, 17(6). |
| Boisson-Vidal, C. et al., “Neoangiogenesis Induced by Progenitor Endothelial Cells: Effect of Fucoidan From Marine Algae,” Cardiovascular & Hematological Agents in Medicinal Chem., Jan. 2007, pp. 67-77, 5(1). |
| Bracco, P. et al., “Comparison of polypropylene and polyethylene terephthalate (Dacron) meshes for abdominal wall hernia repair: A chemical and morphological study,” Hernia, 2005, pp. 51-55, 9 (1), published online Sep. 2004. |
| Canadian Office Action dated Jan. 16, 2017 in Canadian Patent Application No. 2,772,114, 4 pages. |
| Collins, R. et al., “Use of collagen film as a dural substitute: Preliminary animal studies,” Journal of Biomedical Materials Research, Feb. 1991, pp. 267-276, vol. 25. |
| Ellouali, M. et al., “Antitumor Activity of Low Molecular Weight Fucans Extracted from Brown Seaweed Ascophyllum nodosum,” Anticancer Res., Nov.-Dec. 1993, pp. 2011-2020, 12 (6A). |
| Haneji, K. et al., “Fucoidan extracted from Cladosiphon Okamuranus Tokida Induces Apoptosis of Human T-cell Leukemia Virus Type 1-Infected T-Cell Lines and Primary Adult T-Cell Leukemia Cells,” Nutrition and Cancer, 2005, pp. 189-201, 52(2), published online Nov. 2009. |
| Haroun-Bouhedja, F. et al., “In Vitro Effects of Fucans on MDA-MB231 Tumor Cell Adhesion and Invasion,” Anticancer Res., Jul.-Aug. 2002, pp. 2285-2292, 22(4). |
| Haroun-Bouhedja, F. et al., “Relationship between sulfate groups and biological activities of fucans,” Thrombosis Res., Dec. 2000, pp. 453-459, 100(5). |
| Hirano, S. et al., “The blood biocompatibility of chitosan and N-acylchitosans,” J. Biomed. Mater. Res., Apr. 1985, 413-417, 19. |
| International Search Report for Application No. PCT/EP2010/063062 dated Dec. 17, 2010. |
| Junge, K. et al., “Functional and Morphologic Properties of a Modified Mesh for Inguinal Hernia Repair,” World J. Surg., Sep. 2002, pp. 1472-1480, 26. |
| Kanabar, V. et al., “Some structural determinants of the antiproliferative effect of heparin-like molecules on human airway smooth muscle,” Br. J. Pharmacol., Oct. 2005, pp. 370-777, 146(3). |
| Klinge, U. et al., “Foreign Body Reaction to Meshes Used for the Repair of Abdominal Wall Hernias,” Eur J. Surg, Sep. 1999, pp. 665-673, 165. |
| Klinge, U. et al., “Functional and Morphological Evaluation of a Low-Weight, Monofilament Polypropylene Mesh for Hernia Repair,” J. Biomed. Mater. Res., Jan. 2002, pp. 129-136, 63. |
| Langenbech, M. R. et al., “Comparison of biomaterials in the early postoperative period,” Surg Endosc., May 2003, pp. 1105-1109, 17 (7). |
| Logeart, D. et al., “Fucans, sulfated polysaccharides extracted from brown seaweeds, inhibit vascular smooth muscle cell proliferation. II. Degradation and molecular weight effect,” Eur. J. Cell. Biol., Dec. 1997, pp. 385-390, 74(4). |
| Malette, W. G. et al., “Chitosan, A New Hemostatic,” Ann Th. Surg., Jul. 1983, pp. 55-58, 36. |
| Muzzarelli, R .et al., “Reconstruction of parodontal tissue with chitosan,” Biomaterials, Nov. 1989, pp. 598-604, 10. |
| O'Dwyer, P. et al., “Randomized clinical trial assessing impact of a lightweight or heavyweight mesh on chronic pain after inguinal hernia repair,” Br. J. Surg., Feb. 2005, pp. 166-170, 92(2). |
| Preliminary Search Report from French Patent Office dated Dec. 20, 2006, 3 pages. |
| Prokop, A. et al., “Water Soluble Polymers for Immunoisolation I: Complex Coacevation and Cytotoxicity,” Advances in Polymer Science, Jul. 1998, pp. 1-51, 136. |
| Rao, B. et al., “Use of chitosan as a biomaterial: Studies on its safety and hemostatic potential,” J. Biomed. Mater. Res., Jan. 1997, pp. 21-28, 34. |
| Rosen, M. et al., “Laparoscopic component separation in the single-stage treatment of infected abdominal wall prosthetic removal,” Hernia, 2007, pp. 435-440, 11, published online Jul. 2007. |
| Scheidbach, H. et al., “In vivo studies comparing the biocompatibility of various polypropylene meshes and their handling properties during endoscopic total extraperitoneal (TEP) patchplasty: An experimental study in pigs,” Surg. Endosc., Feb. 2004, pp. 211-220, 18(2). |
| Strand, S. et al., “Screening of Chitosans and Conditions for Bacterial Flocculation,” Biomacromolecules, Mar. 2001, 126-133, 2. |
| Varum, K. et al., “In vitro degradation rates of partially N-acetylated chitosans in human serum,” Carbohydrate Research, Mar. 1997, pp. 99-101, 299. |
| Welty, G. et al., “Functional impairment and complaints following incisional hernia repair with different polypropylene meshes,” Hernia, Aug. 2001; pp. 142-147, 5. |
| Zvyagintseva, T. et al., “Inhibition of complement activation by water-soluble polysaccharides of some far-eastern brown seaweeds,” Comparative Biochem and Physiol, Jul. 2000, pp. 209-215, 126(3). |
| Number | Date | Country | |
|---|---|---|---|
| 20210189616 A1 | Jun 2021 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 13393994 | US | |
| Child | 17117083 | US |
